Abstract 2299
Background
The optimal chemotherapy regimen for concurrent chemoradiation in locally advanced non-small cell lung cancer (NSCLC) remains unclear. Cisplatin-etoposide regimen related toxicity is high, weekly regimens have been investigating. We aimed to compare the efficacy and safety of different concurrent chemotherapy regimens in the context.
Methods
A total of 225 patients with locally advanced, unresectable stage III NSCLC included. Patients who treated with weekly docetaxel-platin (DP), paclitaxel-platin (PP) and standard dose etoposide-platin (EP) chemotherapy regimens were selected and divided to groups for the comparison of toxicity, response rate, progression free survival (PFS) and overall survival (OS) rates.
Results
There was statistically significant difference between overall response rate of each treatment groups (DP: 96,1%, PP: 94% and EP:76.7%, p < 0.001). The median PFS rate of patients who treated with DP, PP and EP was 16, 15 and 13.3 months, respectively (p = 0.435). The median OS of patients treated with DP, PP and EP was 19.2, 29.7 and 28.3 months, respectively (p = 0.092). The rates of adverse events such as nausea, vomiting, neuropathy and anaphylaxis was similar. Grade 1-2 mucositis or esophagitis, anemia, pneumonitis were significantly higher in PP group than other groups. However, hematologic toxicities were higher in the EP group than other groups.Table:
1464P
Patients characteristics | ||||
---|---|---|---|---|
DP (N = 102) N(%) | PP (N = 50) N(%) | EP (N = 73) N(%) | P | |
Median age | 61 | 64 | 58 | 0.038 |
Gender Male | 93(91.2) | 48(96) | 64(87.7) | 0.28 |
Histopathology Squamous cell | 53(52) | 31(62) | 43(58.9) | <0.001 |
Stage IIIB-IIIC | 65(63.7) | 31(62) | 41(56.2) | 0.59 |
Conclusions
When the weekly chemotherapy regimens were compared with the standard dose, our study demonstrated similar survival rates but better treatment response rates. Adverse events and toxicity rates were different and depending on the type of chemotherapy regimen used.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Abdurrahman Işıkdogan.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4615 - Proteomic Profiling Identifies Molecular Basis of Adverse Event to BPM31510 Exposure: Rationale for Comprehensive Molecular Pharmacodynamics (PD) in Phase 1 Clinical Trial Design
Presenter: Vivek Subbiah
Session: Poster Display session 1
Resources:
Abstract
5052 - Identification of first-in-class, naturally occurring LAG3 checkpoint inhibitor
Presenter: Gennady Bratslavsky
Session: Poster Display session 1
Resources:
Abstract
5336 - Are Epigenetic therapies modifying sensitivity to conventional chemotherapy?
Presenter: Alexandra Bizot
Session: Poster Display session 1
Resources:
Abstract
5739 - Oncogenic mutations at the dimer interface of EGFR lead to formation of covalent homo-dimers and allosteric activation of the kinase domain: A mechanism which alters the selectivity profile of oncogenic EGFR.
Presenter: Elizabeth Buck
Session: Poster Display session 1
Resources:
Abstract
5492 - Basic selective estrogen receptor degraders (B-SERDs) in combination with novel BET inhibitors in ER+ breast cancer
Presenter: Rui Xiong
Session: Poster Display session 1
Resources:
Abstract
5965 - EPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer
Presenter: Ronan Le Moigne
Session: Poster Display session 1
Resources:
Abstract
3582 - AVID200 neutralizes TGF-beta1 and -beta3, the principal immunosuppressive TGF-beta isoforms overexpressed by tumors, and sensitizes tumors to immune checkpoint inhibitors.
Presenter: Tina Gruosso
Session: Poster Display session 1
Resources:
Abstract
1996 - High NAMPT expression and anti-tumor activity of NAMPT inhibitor in adult T-cell leukemia/lymphoma
Presenter: Tomohiro Kozako
Session: Poster Display session 1
Resources:
Abstract
4307 - TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers
Presenter: Alexander Drilon
Session: Poster Display session 1
Resources:
Abstract
4869 - In Vivo Evaluation of Cisplatin-loaded PEG-PCL Block Copolymeric Nanoparticles for Anticancer Drug Delivery
Presenter: Yingtzu Yen
Session: Poster Display session 1
Resources:
Abstract